Abstract
Emerging technologies such as artificial intelligence are rapidly making their way into fertility clinics around the world. Clinicians, patients, and their families may potentially benefit from rapid advances in the AI field through applications including AI-based embryo selection. Yet, regulation to encourage benefits and diminish risks in AI tools for ART remains underdeveloped, which is unsurprising given its recent entry into the market. Fertility practitioners can play an active role in the regulatory environment for innovative ARTs including AI-based embryo selection — complementing federal regulatory agencies, state medical licensing boards, professional organizations, and civil society entities.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
